Description

Erdafitinib Tablets 3 mg

Erdafitinib Tablets 3 mg are an oral prescription medicine containing erdafitinib, a targeted therapy used for certain cancers with specific genetic alterations. Erdafitinib belongs to a class of medicines known as FGFR inhibitors and works by blocking abnormal signaling from fibroblast growth factor receptors (FGFRs), which can contribute to cancer cell growth.

Erdafitinib may be prescribed for eligible patients with locally advanced or metastatic urothelial carcinoma (bladder cancer) when specific FGFR genetic alterations are present. Treatment suitability depends on the patient’s diagnosis, previous treatments, genetic testing, and overall health.

If you are looking for Erdafitinib 3 mg tablets, consult a qualified healthcare professional to determine whether this medicine is appropriate for your condition. Erdafitinib should be taken exactly as prescribed, and patients may require regular monitoring during treatment.

Key Information

• Active ingredient: Erdafitinib
• Strength: 3 mg
• Dosage form: Tablet
• Drug class: FGFR inhibitor
• Typical use: Certain FGFR-altered advanced or metastatic urothelial carcinoma
• Prescription: Use only under the supervision of a qualified healthcare professional

Frequently Asked Questions

1. What are Erdafitinib 3 mg tablets used for?

2. How does erdafitinib work?
Erdafitinib blocks the activity of certain FGFR proteins. In some cancers, abnormal FGFR signaling can promote cancer cell growth and survival. Blocking these signals may help slow or stop the growth of cancer cells.

3. How should Erdafitinib 3 mg be taken?
Erdafitinib should be taken exactly according to your healthcare professional’s instructions. The dose and treatment schedule may vary depending on your condition and how you respond to treatment. Do not change the dose or stop treatment without medical advice.

4. What are the possible side effects of erdafitinib?
Possible side effects can include dry mouth, diarrhea, fatigue, changes in appetite, skin or nail changes, and changes in phosphate levels. Erdafitinib can also cause serious eye-related problems and other adverse reactions, so regular medical monitoring is important.

5. Does everyone with bladder cancer qualify for erdafitinib?
No. Erdafitinib is intended for specific patients whose cancer has eligible FGFR alterations and who meet other treatment criteria. Genetic or molecular testing may be required before treatment. Your oncologist can determine whether erdafitinib is appropriate for you.